BioPharma Bitez: Nestle, Moderna, and Stan Lee

Happy Friday everybody. Welcome to this week’s edition of “BioPharma Bitez.” Top news in the industry as well as one story outside of it.

So, to kick it off this week, Nestle has increased their stake in Aimmune’s Peanut Allergy medication portfolio up to 276 million dollars with their investment.

Moderna is looking to surpass Allergan’s record-setting IPO from a few weeks ago with their own IPO valued at 500 million dollars.

Dragonfly’s first natural killer treatment is expected to have their first IED filed in Q2 2019, with Celgene adding another 50 million in terms of their stake in the company this week.

uniQure has received positive “phase two-B” clinical data for their gene therapy product for “hemophilia-B,” and that is tightening up the race with Spark Therapeutics own “hemophilia-B” pipeline.  

Roivant is now valued at 7 billion dollars, up from the 5.6 billion dollars for the last year. The differences here is that they’ve added eight more companies for their portfolio and another 20 drugs since last year’s valuation.

So, now, we are going to look at what’s going on outside the industry. The biggest news this week was the sad passing of Stan Lee. One of the most creative minds that we’ve ever had in terms of comic books and other media and has inspired many children and adults throughout their life. So, this week we mourn the loss of one of the great creative minds and wish the best for his family and all of those that knew him.

Thanks again for tuning in this week, I hope to see you next week for another “BioPharma Bitez.”